Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
ZNTL moved a median of 0.00% 30 minutes after news, and -0.04% by the close. How ZNTL actually reacts to news — the realized, point-in-time move the market made, measured across 393 labeled events over the last three years with zero look-ahead.
ZNTL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 393 |
| 30-min | 0.00% | 49% | 393 |
| 60-min | +0.25% | 52% | 393 |
| to close | -0.04% | 45% | 392 |
| Middle 50% of ZNTL reactions | -1.71% to +2.12% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 393 |
Half of all Zentalis Pharmaceuticals, Inc. - common stock news events land between -1.71% and +2.12% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ZNTL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 16 | -0.40% | 50% | -0.38% |
| Coverage initiations | 10 | +1.17% | 70% | -0.38% |
| Rating reiterations | 47 | -0.29% | 45% | -0.29% |
| Price-target cuts | 14 | -1.37% | 29% | +0.42% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ZNTL ranks against every other measured name →
That’s how ZNTL usually reacts — get an email when it moves on news →Email me when ZNTL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ZNTL's baseline. Nothing else.
Recent ZNTL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract | Press release | GlobeNewswire | -4.31% | -0.86% | |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.71% | -4.54% | |
| Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.66% | +8.16% | |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +4.08% | +2.45% | |
| Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +1.87% | -1.87% | |
| Form 8-K Zentalis Pharmaceuticals For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | +4.07% | |
| Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering | Press release | GlobeNewswire | +1.54% | -0.56% | |
| Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering | Press release | GlobeNewswire | +1.54% | -0.56% | |
| Form 10-Q Zentalis Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.03% | -9.83% | |
| Form 8-K Zentalis Pharmaceuticals For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.03% | -9.83% | |
| Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | +2.03% | -9.83% | |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +4.50% | |
| Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 | Press release | GlobeNewswire | +3.03% | -2.15% | |
| Form 8-K Zentalis Pharmaceuticals For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.61% | |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.40% | -0.25% | |
| Form 8-K Zentalis Pharmaceuticals For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -1.19% | +1.50% | |
| Form DEFA14A Zentalis Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -1.19% | +1.50% | |
| Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy | Press release | GlobeNewswire | -1.19% | +1.50% | |
| Form 8-K Zentalis Pharmaceuticals For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +2.76% | -2.64% | |
| Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | Press release | GlobeNewswire | +2.76% | -2.64% | |
| Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.37% | -5.32% | |
| Form 10-Q Zentalis Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.69% | +3.13% | |
| Form 8-K Zentalis Pharmaceuticals For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | +3.13% | |
| Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress | Press release | GlobeNewswire | +1.69% | +3.13% | |
| Form 8-K Zentalis Pharmaceuticals For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +4.77% | +0.49% | |
| Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer | Press release | GlobeNewswire | +4.77% | +0.49% | |
| Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.97% | -2.68% | |
| Form ARS Zentalis Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +2.25% | |
| Form DEF 14A Zentalis Pharmaceuticals For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +2.25% | |
| Form DEFA14A Zentalis Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +2.25% | |
| Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer | Press release | GlobeNewswire | +0.00% | -1.24% | |
| Form 8-K Zentalis Pharmaceuticals For: Apr 17 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | +3.46% | |
| Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 | Press release | GlobeNewswire | -0.11% | +3.46% | |
| Form 8-K Zentalis Pharmaceuticals For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | +4.83% | +52.41% | |
| Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer | Press release | GlobeNewswire | +4.83% | +52.41% | |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.82% | +6.05% | |
| Form 10-K Zentalis Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.54% | -19.23% | |
| Form 8-K Zentalis Pharmaceuticals For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -19.23% | |
| Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates | Press release | GlobeNewswire | -1.54% | -19.23% | |
| Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 | Press release | GlobeNewswire | -1.48% | -7.20% | |
| Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.85% | +1.70% | |
| Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | -3.52% | -10.21% | |
| Form 8-K Zentalis Pharmaceuticals For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -16.75% | -10.05% | |
| Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 | Press release | GlobeNewswire | +0.36% | +29.93% | |
| Form 8-K Zentalis Pharmaceuticals For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | +0.00% | |
| Form 10-Q Zentalis Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.80% | +12.00% | |
| Form 8-K Zentalis Pharmaceuticals For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +4.80% | +12.00% | |
| Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress | Press release | GlobeNewswire | +4.80% | +12.00% | |
| Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.71% | -5.71% | |
| Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.36% | -3.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ZNTL section they belong to.
Where else ZNTL is measured.
ZNTL earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Zentalis Pharmaceuticals, Inc. - common stock's median reaction calculated?
Every labeled ZNTL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 393 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of ZNTL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ZNTL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.